Stay updated with breaking news from Program Guidance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Biden administration is moving to implement the new electric vehicle charging station programs and $7.5 billion in new federal funds provided by the Infrastructure Investment and...
Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies driven by...
Difficulties faced by medical staff peer review committees and compliance departments in quickly identifying and coordinating with each other to address False Claims Act exposure for alleged medically unnecessary or substandard care.
Signatory companies submit annual certifications attesting that they have policies and procedures in place to foster compliance with the Code.
Share this article LEXINGTON, Mass., April 12, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is re-issuing this press release solely to correct inadvertent typographical errors under the heading "Updated PUR1800 Program Guidance" which incorrectly noted that Pulmatrix plans to initiate a PUR1800 Phase 2 proof-of-concept efficacy study for the treatment of AECOPD in 2021. This study is not expected to commence until 2022 All other data and disclosure remain unchanged. The corrected press release reads in its entirety as follows: LEXINGTON, Mass., April 12, 2021 – Pulmatrix, Inc. ...